Catalyst Pharma: Independent Committee Recommends To Continue Firdapse Trial

(RTTNews) - Catalyst Pharmaceutical Partners, Inc. (CPRX) announced an independent Data Monitoring Committee overseeing the company's ongoing pivotal Phase 3 clinical trial evaluating Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome recommended that the trial be continued as planned based on the committee's review of safety and clinical data from the trial.

The Firdapse Phase 3 clinical trial is designed as a randomized, double-blind, placebo-controlled, discontinuation trial enrolling 36 patients diagnosed with Lambert-Eaton Myasthenic Syndrome. The trial is being conducted at 22 centers in the United States, Canada, South America and Europe.